Díaz Luis Antonio, Fuentes-López Eduardo, Ayares Gustavo, Idalsoaga Francisco, Arnold Jorge, Márquez-Lomas Andrea, Ramírez Carolina A, Medel María Paz, Viñuela Francisca, Lacalle Lucas, Roblero Juan Pablo, Ferreccio Catterina, Lazo Mariana, Brahmania Mayur, Singal Ashwani K, Dirchwolf Melisa, Méndez-Sánchez Nahum, Chavez-Tapia Norberto, Guerra Patricia, Restrepo Juan Carlos, Oliveira Claudia P, Lombardo Julissa, Sánchez Abel, Elizondo Martín, Tagle Martín, Padilla Martín, Sánchez Marco, Carrera Enrique, Girala Marcos, Chery Omega, Castellanos-Fernández Marlen, Barrera Francisco, Lazarus Jeffrey V, Kamath Patrick S, Bataller Ramon, Arrese Marco, Arab Juan Pablo
Departamento de Gastroenterología, Pontificia Universidad Católica de Chile, Santiago, Chile.
Departamento de Ciencias de la Salud, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Lancet Gastroenterol Hepatol. 2022 Jun;7(6):552-559. doi: 10.1016/S2468-1253(22)00008-5. Epub 2022 Apr 14.
Non-alcoholic fatty liver disease (NAFLD) affects 20-25% of the general population and is associated with morbidity, increased mortality, and elevated health-care costs. Most NAFLD risk factors are modifiable and, therefore, potentially amenable to being reduced by public health policies. To date, there is no information about NAFLD-related public health policies in the Americas. In this study, we analysed data from 17 American countries and found that none have established national public health policies to decrease NAFLD-related burden. There is notable heterogeneity in the existence of public health policies to prevent NAFLD-related conditions. The most common public health policies were related to diabetes (15 [88%] countries), hypertension (14 [82%] countries), cardiovascular diseases (14 [82%] countries), obesity (nine [53%] countries), and dyslipidaemia (six [35%] of countries). Only seven (41%) countries had a registry of the burden of NAFLD, and efforts to raise awareness in the Americas were scarce. The implementation of public health policies are urgently needed in the Americas to decrease the burden of NAFLD.
Lancet Gastroenterol Hepatol. 2022-6
Lancet Gastroenterol Hepatol. 2020-5-12
J Pak Med Assoc. 2020-12
Ann Hepatol. 2014
Turk J Gastroenterol. 2019-10
Transl Gastroenterol Hepatol. 2025-7-8
Liver Int. 2025-5
Commun Med (Lond). 2024-10-29